

STEP THERAPY POLICY

- POLICY:** Ophthalmic Nonsteroidal Anti-Inflammatory Drugs Step Therapy Policy
- Acular® (ketorolac tromethamine 0.5% ophthalmic solution – Allergan, generics)
 - Acular LS® (ketorolac tromethamine 0.4% ophthalmic solution – Allergan, generics)
 - Acuvail® (ketorolac tromethamine 0.45% ophthalmic solution – Allergan)
 - Bromfenac 0.09% ophthalmic solution (generics only)
 - Diclofenac 0.1% ophthalmic solution (generics only)
 - Flurbiprofen 0.03% ophthalmic solution (generics only)
 - Nevanac® (nepafenac 0.1% ophthalmic suspension – Alcon)

REVIEW DATE: 10/07/2020; selected revision 03/10/2021

OVERVIEW

In general, the ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated for the management of **ocular pain and inflammation in the postoperative setting**.¹⁻⁶ Note that the specific labeled indications may differ among the products. Ketorolac 0.5% ophthalmic solution is also indicated for the treatment of seasonal allergic conjunctivitis.¹ Flurbiprofen 0.03% ophthalmic solution is the only ophthalmic NSAID that is not indicated for use in the postoperative setting; flurbiprofen is indicated for the inhibition of intraoperative miosis.⁷

The dosing frequency for the ophthalmic NSAID products range from once daily to four times a day.¹⁻⁶ Flurbiprofen 0.03% ophthalmic solution is dosed before surgery.⁷ Nevanac is an ophthalmic suspension and must be shaken well before use.⁴

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration. Note: Ilevro and Prolensa are not included in this policy.

Automation: A patient with a history of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic ketorolac 0.5% ophthalmic solution, generic ketorolac 0.4% ophthalmic solution, generic bromfenac 0.09% ophthalmic solution, generic diclofenac 0.1% ophthalmic solution, generic flurbiprofen 0.03% ophthalmic solution

Step 2: Acular, Acular LS, Acuvail, Nevanac

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. No other exceptions are recommended.

REFERENCES

Ophthalmic Nonsteroidal Anti-Inflammatory Drugs Step Therapy Policy

Page 2

1. Acular[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan, Inc.; May 2012.
2. Acular LS[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan, Inc.; June 2016.
3. Acuvail[®] ophthalmic solution [prescribing information]. Irvine, CA: Allergan, Inc.; February 2019.
4. Nevanac[®] ophthalmic suspension [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc.; December 2017.
5. Bromfenac 0.09% ophthalmic solution [prescribing information]. Bridgewater, NJ: Alembic Pharmaceutical, Inc; March 2017.
6. Diclofenac 0.1% ophthalmic solution [prescribing information]. Lake Forest, IL: Akorn; June 2016.
7. Flurbiprofen 0.03% ophthalmic solution [prescribing information]. Bridgewater, NJ: Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC; July 2016.